Close Menu
Home › Oxford Nanopore

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

 

CEO: Gordon Sanghera

Website: www.nanoporetech.com

Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

Apr 19, 2019

Oxford Nanopore Sequencing Shows Promise for Diagnosing Prosthetic Joint Infections

Premium

The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.

Oct 05, 2018

Potential Diagnostic Metabolites Detected With Nanopore Method

A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.

Jul 24, 2017

Nanopore Sequencing, PCR Platforms Evaluated for Rapid Pneumonia Diagnosis in UK Study

Premium

The Inhale project is assessing respiratory disease tests on Oxford Nanopore's MinIon and PCR platforms from Curetis and BioMérieux's BioFire Diagnostics.

Sep 26, 2016

UK Team Demonstrates MinIon for UTI Dx, Plans to Develop Sepsis and Respiratory Infection Tests

Premium

Researchers have shown that metagenomic sequencing on the MinIon can identify the pathogen and antimicrobial resistance profile of UTIs in several hours. 

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.